ROCKVILLE, Md. — October 29, 2025 — Leads & Copy — NovaBridge Biosciences (Nasdaq: NBP) announced that its Visara subsidiary has assigned its exclusive license agreement to Everest Medicines (HKEX: 1952) for VIS-101 development in Greater China and other Asian countries.
NovaBridge also appointed Ian Woo, President and CFO of Everest Medicines, to its Board of Directors. The VIS-101 biologic targets VEGF-A/ANG2 and is completing Phase 2 study in China, expected to be Phase 3-ready in 2026.
Sean Fu, CEO of NovaBridge, said the agreement aligns with the company’s focus on collaborating with global innovators. Emmett T. Cunningham, Jr. MD, PhD, MPH, Co-Founder and Executive Chairman of Visara, believes Everest Medicines’ expertise could accelerate VIS-101’s development.
Ian Woo, President and CFO of Everest Medicines, said the partnership brings a differentiated asset to Everest’s pipeline, paving the way for entry into the ophthalmology market.
Visara acquired exclusive rights for VIS-101 globally through an assignment agreement with AffaMed and a direct license with AskGene. Visara has assigned its direct license with AskGene to Everest Medicines to develop, manufacturing and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries.
VIS-101 is completing a Phase 2 study in China and is expected to be Phase 3-ready in 2026. Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.
NovaBridge’s differentiated pipeline is led by givastomig and VIS-101.
PJ Kelleher, LifeSci Advisors, +1-617-430-7579, pkelleher@lifesciadvisors.com
Kyler Lei, NovaBridge, +1-240-745-6330, kyler.lei@imabbio.com
IR@imabbio.com
Source: NovaBridge Biosciences
